Sygnature Discovery ranked in FT1000
Sygnature Discovery, UK provider of integrated drug discovery resource and expertise, has been ranked in the Financial Times list of Europe’s fastest growing companies, FT1000.
Compiled in collaboration with Statista, the FT1000 list the European companies that have achieved the highest percentage growth in revenues. Sygnature Discovery was ranked 906th in Europe and was featured in the top 200 fastest growing UK-based companies.
“It is a significant achievement for Sygnature Discovery to be included in the FT1000 and demonstrates the increasing demand that we are seeing for our integrated drug discovery expertise from pharmaceutical and biotech clients worldwide,” commented Dr Paul J. Clewlow, senior VP, business development of Sygnature Discovery. “There are only five other pharmaceutical companies in this list of Europe’s 1,000 fastest growing companies.”